Summary & Overview
HCPCS J0881: Darbepoetin Alfa Injection, 1 microgram (Non-ESRD)
HCPCS Level II code J0881 denotes an injection of darbepoetin alfa, 1 microgram, for non-ESRD indications. As an erythropoiesis-stimulating agent used to manage anemia in patients with chronic disease or receiving certain cancer treatments, this code captures pharmacy-administered biologic therapy delivered in outpatient settings. Nationally, use of ESAs affects clinical workflows, drug acquisition costs, and payer coverage policies due to safety considerations and bundled payment arrangements.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ESA use, payer coverage patterns, common billing considerations for administration in outpatient infusion centers and physician offices, and benchmarking elements when available. The publication summarizes typical sites of service, payer scope, and operational implications for billing and claims processing. Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, or related codes are noted as missing and are not included.
Billing Code Overview
HCPCS Level II code J0881 represents an injection of darbepoetin alfa, 1 microgram, indicated for non-end-stage renal disease (non-ESRD) use. This medication is an erythropoiesis-stimulating agent (ESA) commonly administered to treat anemia associated with certain chronic conditions or cancer therapies.
-
Service type: Injectable biologic therapy
-
Typical site of service: Outpatient infusion or injection clinic, physician office, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with anemia of chronic disease (non‑ESRD) such as chemotherapy‑induced anemia, myelodysplastic syndrome, or anemia related to chronic inflammatory conditions who requires erythropoiesis‑stimulating therapy. The patient presents to an outpatient infusion center or physician office for administration of J0881 (darbepoetin alfa, per 1 microgram) as an injection. The clinical workflow includes: pre‑visit medication reconciliation and baseline labs (hemoglobin, iron studies, B12/folate as indicated), clinician assessment documenting indication and target hemoglobin, determination of dose (converted to micrograms), scheduling of injection (subcutaneous or intravenous per protocol), preparation of the drug by nursing per medication safety checks, administration with documentation of lot number and dose, observation for acute reactions, and post‑administration instructions including lab monitoring schedule and follow‑up appointment for dose adjustment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug amount discarded/not administered to complete single dose unit | When partial vial or syringe is discarded and payer requires reporting of wasted drug for single‑dose vial billing rules |